Skip to content

PrEP (Pre-exposure Prophylaxis) Stigma and Women Ethnodrama Pilot Phase

Designing an Ethnodrama Addressing PrEP Stigma Toward Young Cisgender Women in Kenya

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07225894
Enrollment
144
Registered
2025-11-10
Start date
2025-12-01
Completion date
2026-03-17
Last updated
2026-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Keywords

Stigma, HIV, PrEP

Brief summary

The investigators will pilot test an ethnodrama intervention designed to transform community member beliefs about and foster support of young cisgender women (YCW) using Pre-exposure Prophylaxis (PrEP).

Detailed description

In Aim 3, the investigators will pilot test the ethnodrama intervention (i.e., six plays on reducing PrEP stigma toward young women) that were pre-tested in Aim 2. The pilot evaluation will focus on evaluating logistical feasibility and describing participants' perceptions of the intervention's influence on PrEP-related stigma toward young women.

Interventions

The intervention is six drama performances that are designed to transform community member beliefs about and foster support of young women's PrEP use, reduce PrEP-related enacted stigma toward young women, and reduce PrEP-related anticipated and internalized stigma among young women.

Sponsors

Duke University
Lead SponsorOTHER
National Institutes of Health (NIH)
CollaboratorNIH
Fogarty International Center of the National Institute of Health
CollaboratorNIH

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Inclusion: * Young women who are currently using or have previously used PrEP * Community members (adult women and men) who will be identified from the audience during the first play in a round * Adult audience members (female and male) who heard about the play from the public announcements and chose to attend and watch the play Exclusion: * N/A

Design outcomes

Primary

MeasureTime frame
Feasibility of the drama intervention as measured by the number of plays performed as intendedUp to 1 month post-intervention
Feasibility of the drama intervention as measured by the number of study procedures implemented easilyUp to 1 month post-intervention
Feasibility of the drama intervention as measured by the estimated number of audience membersUp to 1 month post-intervention

Secondary

MeasureTime frameDescription
Potential effectiveness of the intervention's storylines on transforming audience members' PrEP-related perceptions as measured by a brief interviewer-administered survey using the Narrative Transportation Scale (NTS)Immediately post-interventionThe 12-item scale is divided into two sub-scales: engagement and personal connection. Sample items include: "I wanted to learn what happened to the women after the story ended"; "The stories in the dramas are relevant to my everyday life"; and "The stories in the drama are realistic and believable." The total score ranges from 12 to 84, where a higher score indicates greater narrative transportation.
PrEP (Pre-exposure Prophylaxis) stigmaBaseline, immediately post-intervention, and up to 3 months post-interventionThe investigators will administer the survey at three distinct time points to assess descriptive changes in stigma-related perceptions among young women. The first administration will occur prior to the implementation of any play performances to establish baseline measures (e.g., up to several weeks prior to the first play). The second administration will take place immediately after participants have attended all six plays (e.g., up to two weeks after the last play), capturing immediate post-intervention responses. The third and final administration will occur up to three months following the last performance to assess sustained impact over time.

Countries

Kenya

Contacts

PRINCIPAL_INVESTIGATORAmy Corneli, PhD, MPH

Duke University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 5, 2026